The NeuroChat series continues with a great Q&A with Dr. Karen Gregory from Monash University. Karen is an outstanding, world-leading neuropharmacologist and has published many seminal papers on mGlu receptors and allosteric modulation of GPCRs. After a postdoc in the United States at the VCNDD, Karen returned home as an Australian Research Council Future Fellow, level C Senior Research Fellow, equivalent to Associate Professor within the U.S. system. Never one to be idle, Karen co-leads the Endocrine and Neuropharmacology lab in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Sciences, and was recently appointed as the Therapeutic Program Area (Neuroscience) Coordinator to enhance multidisciplinary research and tackle the “big” challenges in neuroscience drug discovery. Karen brings unique insight of great value in the Q&A—I invite you to read the discussion below.